Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RAPP

Rapport Therapeutics Inc.

Sep 27 • 04:00PM ET

21.33

Dollar change +0.80
Percentage change 3.90	%

Healthcare • Biotechnology • USA • NASD

Held by: IWM IWO VTI SCHA IWN IWC VXF SCHB RSSL VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	50.86%	Shs Outstand	36.58M	Perf Week	0.47%
Market Cap	780.25M	Forward P/E	-	EPS next Y	-	Insider Trans	3.35%	Shs Float	17.97M	Perf Month	5.70%
Income	-	PEG	-	EPS next Q	-0.56	Inst Own	51.34%	Short Float	7.75%	Perf Quarter	-8.30%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	8.34	Perf Half Y	-
Book/sh	9.21	P/B	2.32	EPS next Y	-	ROA	-	Short Interest	1.39M	Perf Year	-
Cash/sh	9.19	P/C	2.32	EPS next 5Y	-	ROE	-	52W Range	16.55 - 28.08	Perf YTD	2.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-24.04%	Beta	-
Dividend TTM	-	Quick Ratio	42.08	Sales past 5Y	0.00%	Gross Margin	-	52W Low	28.88%	ATR (14)	1.92
Dividend Ex-Date	-	Current Ratio	42.08	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	54.08	Volatility	8.67% 9.26%
Employees	58	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	35.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.66	Prev Close	20.53
Sales Surprise	-	EPS Surprise	-183.33%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	167.12K	Price	21.33
SMA20	5.79%	SMA50	3.39%	SMA200	-2.28%	Trades		Volume	110,339	Change	3.90%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-02-24	Initiated	TD Cowen	Buy
Jul-02-24	Initiated	Stifel	Buy	$35
Jul-02-24	Initiated	Jefferies	Buy	$35

Sep-05-24 07:00AM	Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences (GlobeNewswire)
Aug-29-24 07:00AM	Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
Aug-08-24 07:00AM	Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update (GlobeNewswire)
Aug-06-24 06:30AM	3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns (InvestorPlace)
Jul-29-24 07:00AM	Rapport Therapeutics to Present Data for TARP 8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain (GlobeNewswire)
02:22PM	Loading…
Jul-05-24 02:22PM	Hedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and More (Insider Monkey)
Jun-12-24 04:01PM	Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire) +9.02%
Jun-06-24 06:54PM	Rapport Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HEALY JAMES	Director	Jul 01 '24	Buy	24.52	44,032	1,079,575	40,851	Jul 03 08:04 PM
HEALY JAMES	Director	Jun 10 '24	Buy	17.00	558,824	9,500,008	1,863,327	Jun 10 07:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RAPP

Rapport Therapeutics Inc.

Upgrade your FINVIZ experience